blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3601533

EP3601533 - PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  22.01.2021
Database last updated on 16.05.2026
FormerGrant of patent is intended
Status updated on  16.12.2020
FormerExamination is in progress
Status updated on  18.11.2020
FormerGrant of patent is intended
Status updated on  09.11.2020
FormerExamination is in progress
Status updated on  03.06.2020
FormerRequest for examination was made
Status updated on  03.01.2020
FormerThe international publication has been made
Status updated on  06.10.2018
Formerunknown
Status updated on  23.03.2018
Most recent event   Tooltip09.04.2026Deletion: Date of oral proceedings 
Applicant(s)For all designated states
Iovance Biotherapeutics, Inc.
825 Industrial Road
Suite 400
San Carlos, CA 94070 / US
[2022/16]
Former [2020/06]For all designated states
Iovance Biotherapeutics, Inc.
999 Skyway Road
Suite 150
San Carlos, CA 94070 / US
Inventor(s)01 / WARDELL, Seth
30204 USF Holly Drive
Tampa, FL 33620 / US
02 / BENDER, James
3 Cloverdale
Rancho Santa Margarita, CA 92688 / US
03 / LOTZE, Michael, T.
5134 Westminster Place
Pittsburgh, PA 15232 / US
 [2020/06]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstraße 4
80802 München / DE
[N/P]
Former [2020/06]Secerna LLP
The Old Fire Station
18 Clifford Street
York YO1 9RD / GB
Application number, filing date18709132.705.01.2018
[2020/06]
WO2018US12633
Priority number, dateUS201762478506P29.03.2017         Original published format: US 201762478506 P
US201762539410P31.07.2017         Original published format: US 201762539410 P
US201762548306P21.08.2017         Original published format: US 201762548306 P
US201762554538P05.09.2017         Original published format: US 201762554538 P
US201762559374P15.09.2017         Original published format: US 201762559374 P
US201762567121P02.10.2017         Original published format: US 201762567121 P
US201762577655P26.10.2017         Original published format: US 201762577655 P
US201762582874P07.11.2017         Original published format: US 201762582874 P
US201762596374P08.12.2017         Original published format: US 201762596374 P
[2020/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018182817
Date:04.10.2018
Language:EN
[2018/40]
Type: A1 Application with search report 
No.:EP3601533
Date:05.02.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 04.10.2018 takes the place of the publication of the European patent application.
[2020/06]
Type: B1 Patent specification 
No.:EP3601533
Date:24.02.2021
Language:EN
[2021/08]
Search report(s)International search report - published on:EP04.10.2018
ClassificationIPC:C12N5/0783, C12M1/04
[2020/06]
CPC:
A61K31/675 (EP,IL,KR,US); A61K35/17 (EP,IL,US); C12N5/0638 (EP,IL,KR,US);
A01N1/162 (IL,KR,US); A61K31/7076 (EP,IL,KR,US); A61K38/2013 (EP,IL,KR,US);
A61K38/217 (IL,US); A61K40/11 (EP,IL,KR,US); A61K40/428 (EP,IL,US);
A61K9/0019 (IL,KR,US); A61P35/00 (EP,IL,KR,US); C12N5/0634 (EP,IL,US);
C12N5/0636 (EP,IL,US); A61K2039/5154 (US); A61K2039/5156 (US);
A61K2039/5158 (US); A61K2039/55533 (IL,US); A61K2121/00 (KR);
A61K2300/00 (KR); A61K39/0011 (US); A61K40/50 (EP,IL,US);
C12N2500/90 (EP,IL); C12N2501/04 (EP,IL,KR,US); C12N2501/2302 (EP,IL,KR,US);
C12N2501/2315 (EP,IL,KR,US); C12N2501/2321 (EP,IL,KR,US); C12N2501/24 (EP,IL,KR,US);
C12N2501/603 (EP,IL,US); C12N2502/11 (EP,IL,KR,US); C12N2506/30 (IL,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/06]
Extension statesBA18.10.2019
ME18.10.2019
Validation statesMA18.10.2019
MD18.10.2019
TitleGerman:VORGÄNGE ZUR HERSTELLUNG VON TUMORINFILTRIERENDEN LYMPHOZYTEN UND DEREN VERWENDUNGEN IN DER IMMUNTHERAPIE[2020/06]
English:PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY[2020/06]
French:PROCÉDÉS DE PRODUCTION DE LYMPHOCYTES INFILTRANT LES TUMEURS ET LEURS UTILISATIONS EN IMMUNOTHÉRAPIE[2020/06]
Entry into regional phase18.10.2019National basic fee paid 
18.10.2019Designation fee(s) paid 
18.10.2019Examination fee paid 
Examination procedure18.10.2019Examination requested  [2020/06]
18.10.2019Date on which the examining division has become responsible
25.02.2020Amendment by applicant (claims and/or description)
08.06.2020Despatch of a communication from the examining division (Time limit: M04)
21.09.2020Reply to a communication from the examining division
10.11.2020Communication of intention to grant the patent
16.11.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
23.12.2020Communication of intention to grant the patent
19.01.2021Fee for grant paid
19.01.2021Fee for publishing/printing paid
19.01.2021Receipt of the translation of the claim(s)
Divisional application(s)EP20161179.5  / EP3730608
EP20161276.9  / EP3722415
EP20183493.4  / EP3766964
EP21175134.2  / EP3910055
EP23195819.0  / EP4279574
Opposition(s)Opponent(s)01  24.11.2021   
Maiwald GmbH
Elisenhof, Elisenstrasse 3
80335 München / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 [N/P]
Former [2021/52]
Opponent(s)01  24.11.2021   
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof, Elisenstrasse 3
80335 München / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
06.12.2021Invitation to proprietor to file observations on the notice of opposition
14.04.2022Reply of patent proprietor to notice(s) of opposition
27.02.2024Date of oral proceedings
28.03.2024Despatch of interlocutory decision in opposition
28.03.2024Despatch of minutes of oral proceedings
Appeal following opposition23.05.2024Appeal received No.  T0734/24
23.05.2024Payment of appeal fee
29.07.2024Statement of grounds filed
27.05.2024Appeal received No.  T0734/24
27.05.2024Payment of appeal fee
26.07.2024Statement of grounds filed
Fees paidRenewal fee
14.01.2020Renewal fee patent year 03
13.01.2021Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XDY] US2012244133  (ROSENBERG STEVEN A et al.)
 [XY] WO2016053338  (US HEALTH et al.)
 [Y] WO2013057500  (CELL MEDICA LTD et al.)
 [Y] WO2013088147  (CELL MEDICA LTD et al.)
by applicantUS2014328791
 WO2012065086
 US4766106
 US5206344
 US5089261
 US4902502
 US6706289
 US2012244133
 US2016010058
 WO2015189356
 WO2015189357
 US2005106717
 US2014377739
 WO2014210036
 US2013115617
 WO2013188427
 US2011136228
 US8809050
 WO2011072088
 US2016208216
 WO2012129201
 US2013102075
 US8956860
 WO2013173835
 US2015175966
 US8008449
 US7943743
 US2011052530
   GATTINONI ET AL., NAT. REV. IMMUNOL., vol. 6, 2006, pages 383 - 393
   DUDLEY ET AL., SCIENCE, vol. 298, 2002, pages 850 - 54
   DUDLEY ET AL., J. CLIN. ONCOL., vol. 23, 2005, pages 2346 - 57
   DUDLEY ET AL., J. CLIN. ONCOL., vol. 26, 2008, pages 5233 - 39
   RIDDELL ET AL., SCIENCE, vol. 257, 1992, pages 238 - 41
   DUDLEY ET AL., J. IMMUNOTHER., vol. 26, 2003, pages 332 - 42
   CHANG ET AL., NAT. IMMUNOL., vol. 17, 2016, pages 364
   CHANG ET AL., NAT. IMMUNOL., vol. 17, no. 364, 2016
   NELSON, J. IMMUNOL., vol. 172, 2004, pages 3983 - 88
   MALEK, ANNU. REV. IMMUNOL., vol. 26, 2008, pages 453 - 79
   STEINKE; BORISH, RESPIR. RES., vol. 2, 2001, pages 66 - 70
   FRY; MACKALL, BLOOD, vol. 99, 2002, pages 3892 - 904
   FEHNIGER; CALIGIURI, BLOOD, vol. 97, 2001, pages 14 - 32
   SPOLSKI; LEONARD, NAT. REV. DRUG. DISC., vol. 13, 2014, pages 379 - 95
   ROSENBERG ET AL., NEW ENG. J. OF MED., vol. 319, 1988, pages 1676
   SWARTZ ET AL., CANCER RES., vol. 72, 2012, pages 2473
   DONIA, SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 75, 2012, pages 157 - 167
   DUDLEY ET AL., CLIN CANCER RES, vol. 16, 2010, pages 6122 - 6131
   HUANG ET AL., J IMMUNOTHER, vol. 28, no. 3, 2005, pages 258 - 267
   BESSER ET AL., CLIN CANCER RES, vol. 19, no. 17, 2013, pages OF1 - OF9
   BESSER ET AL., J IMMUNOTHER, vol. 32, 2009, pages 415 - 423
   ROBBINS ET AL., J IMMUNOL, vol. 173, 2004, pages 7125 - 7130
   SHEN ET AL., J IMMUNOTHER, vol. 30, 2007, pages 123 - 129
   ZHOU ET AL., J IMMUNOTHER, vol. 28, 2005, pages 53 - 62
   TRAN ET AL., J IMMUNOTHER, vol. 31, 2008, pages 742 - 751
   TRAN ET AL., J. IMMUNOTHER., vol. 31, 2008, pages 742 - 51
   TRAN KQ; ZHOU J; DURFLINGER KH ET AL., J IMMUNOTHER, vol. 31, 2008, pages 742 - 751
   DUDLEY ME; WUNDERLICH JR; SHELTON TE ET AL., JIMMUNOTHER, vol. 26, 2003, pages 332 - 342
   JIN ET AL., J. IMMUNOTHERAPY, vol. 35, 2012, pages 283 - 292
   SADEGHI ET AL., ACTA ONCOLOGICA, vol. 52, 2013, pages 978 - 986
   JIN ET AL., J. IMMUNOTHERAPY, vol. 35, no. 3, 2012, pages 283 - 292
   GOFF ET AL., J. CLINICAL ONCOLOGY, vol. 34, no. 20, 2016, pages 2389 - 239
   DUDLEY ET AL., JIMMUNOTHER., vol. 26, 2003, pages 332 - 342
   GOFF ET AL., J IMMUNOTHER., vol. 33, 2010, pages 840 - 847
   MULLANY ET AL., ENDOCRINOLOGY, vol. 153, 2012, pages 1585 - 92
   FONG ET AL., J. OVARIAN RES., vol. 2, 2009, pages 12
   HERREROS-VILLANUEVA ET AL., WORLD J. GASTROENTEROL., vol. 18, 2012, pages 1286 - 1294
   FANTOZZI, BREAST CANCER RES., vol. 8, 2006, pages 212
   DAMSKY ET AL., PIGMENT CELL & MELANOMA RES., vol. 23, 2010, pages 853 - 859
   MEUWISSEN ET AL., GENES & DEVELOPMENT, vol. 19, 2005, pages 643 - 664
   KIM, CLIN. EXP. OTORHINOLARYNGOL., vol. 2, 2009, pages 55 - 60
   SANO, HEAD NECK ONCOL., vol. 1, 2009, pages 32
   GASSNER ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 60, 2011, pages 75 - 85
   MURANSKI ET AL., NAT. CLIN. PRACT. ONCOL., vol. 3, 2006, pages 668 - 681
   DUDLEY ET AL., J. CLIN. ONCOL., vol. 26, 2008, pages 5233 - 5239
   DUDLEY ET AL., J. CLIN. ONCOL., vol. 23, 2005, pages 2346 - 2357
   O'DAY ET AL., J. CLIN. ONCOL., vol. 17, 1999, pages 2752 - 61
   ETON ET AL., CANCER, vol. 88, 2000, pages 1703 - 9
   RADVANYI ET AL., CLIN CANCER RES, vol. 18, 2012, pages 6758 - 6770
   NUCLEIC ACIDS RES., vol. 30, no. 10, 15 May 2002 (2002-05-15), pages e47
   LEUKEMIA, vol. 27, 2013, pages 897 - 906
   GRUIJL ET AL.: "IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells, Santegoets, S. J.", J TRANSL MED., vol. 11, 2013, pages 31, Retrieved from the Internet
   BUCK ET AL., JEM, vol. 212, 2015, pages 1345 - 1360
   J IMMUNOL., vol. 175, no. 10, 15 November 2005 (2005-11-15), pages 7046 - 52
   CLIN CANCER RES., vol. 17, no. 13, 1 July 2011 (2011-07-01), pages 4550 - 4557
   CLIN CANCER RES, vol. 18, no. 24, pages 6758 - 70
   GOFF SL; DUDLEY ME; CITRIN DE; SOMERVILLE RP; WUNDERLICH JR; DANFORTH DN; ZLOTT DA; YANG JC; SHERRY RM; KAMMULA US: "Randomized, Prospective Evaluation Comparing Intensity ofLymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma", J CLIN ONCOL., vol. 34, no. 20, 10 July 2016 (2016-07-10), pages 2389 - 97
   HINRICHS CS; ROSENBERG SA: "Exploiting the curative potential of adoptive T-cell therapy for cancer", IMMUNOL REV., vol. 257, no. 1, January 2014 (2014-01-01), pages 56 - 71, XP055249662, DOI: doi:10.1111/imr.12132

DOI:   http://dx.doi.org/10.1111/imr.12132
   JIN J; SABATINO M; SOMERVILLE R; WILSON JR; DUDLEY ME; STRONCEK DF; ROSENBERG SA: "Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment", J IMMUNOTHER, vol. 35, no. 3, April 2012 (2012-04-01), pages 283 - 92, XP008153078, DOI: doi:10.1097/CJI.0b013e31824e801f

DOI:   http://dx.doi.org/10.1097/CJI.0b013e31824e801f
   SOMERVILLE RP; DEVILLIER L; PARKHURST MR; ROSENBERG SA; DUDLEY ME: "Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE@ bioreactor", J TRANSL MED., vol. 10, 4 April 2012 (2012-04-04), pages 69, XP021126773, DOI: doi:10.1186/1479-5876-10-69

DOI:   http://dx.doi.org/10.1186/1479-5876-10-69
   DONIA M; LARSEN SM; MET O; SVANE IM: "Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor", CYTOTHERAPY, vol. 16, no. 8, August 2014 (2014-08-01), pages 1117 - 20, XP055296812, DOI: doi:10.1016/j.jcyt.2014.02.004

DOI:   http://dx.doi.org/10.1016/j.jcyt.2014.02.004
   HENNING AL; LEVITT DE; VINGREN JL; MCFARLIN BK: "Measurement of T-Cell Telomere Length Using Amplified-Signal FISH Staining and Flow Cytometry", CURR PROTOC CYTOM., vol. 79, 5 January 2017 (2017-01-05), pages 7.47.1 - 7.47.10
   KELESIDIS T; SCHMID 1: "Assessment of Telomere Length, Phenotype, and DNA Content", CURR PROTOC CYTOM., vol. 79, 5 January 2017 (2017-01-05), pages 7.26.1 - 7.26.23
   GARDNER M; BANN D; WILEY L; COOPER R; HARDY R; NITSCH D; MARTIN-RUIZ C; SAYER AA; BARBIERI M; BEKAERT S: "Halcyon study team.. Gender and telomere length: systematic review and meta-analysis", EXP GERONTOL, vol. 51, March 2014 (2014-03-01), pages 15 - 27
   CARBONARI M; TEDESCO T; FIORILLI M: "Correlation between terminal restriction fragments and flow-FISH measures in samples over wide range telomere lengths", CELL PROLIF., vol. 47, no. 1, February 2014 (2014-02-01), pages 20 - 7
   RUFER N; DRAGOWSKA W; THORNBURY G; ROOSNEK E; LANSDORP PM: "Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry", NAT BIOTECHNOL., vol. 16, no. 8, August 1998 (1998-08-01), pages 743 - 7
   LI Y; LIU S; HERNANDEZ J; VENCE L; HWU P; RADVANYI L: "MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro", J IMMUNOL., vol. 184, no. 1, 1 January 2010 (2010-01-01), pages 452 - 65, XP055210596, DOI: doi:10.4049/jimmunol.0901101

DOI:   http://dx.doi.org/10.4049/jimmunol.0901101
   ROSENBERG SA; DUDLEY ME: "Adoptive cell therapy for the treatment of patients with metastatic melanoma", CURR OPIN IMMUNOL., vol. 21, no. 2, April 2009 (2009-04-01), pages 233 - 40, XP026058401, DOI: doi:10.1016/j.coi.2009.03.002

DOI:   http://dx.doi.org/10.1016/j.coi.2009.03.002
   SHEN X; ZHOU J; HATHCOCK KS; ROBBINS P; POWELL DJ JR; ROSENBERG SA; HODES RJ: "Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length", J IMMUNOTHER, vol. 30, no. 1, January 2007 (2007-01-01), pages 123 - 9
   ZHOU J; SHEN X; HUANG J; HODES RJ; ROSENBERG SA; ROBBINS PF: "Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy", J IMMUNOL., vol. 175, no. 10, 15 November 2005 (2005-11-15), pages 7046 - 52
   MACIEJOWSKI J; DE LANGE T: "Telomeres in cancer: tumour suppression and genome instability", NAT REV MOL CELL BIOL., vol. 18, no. 3, March 2017 (2017-03-01), pages 175 - 186
   ERDEL F; KRATZ K; WILLCOX S; GRIFFITH JD; GREENE EC; DE LANGE T: "Telomere Recognition and Assembly Mechanism of Mammalian Shelterin", CELL REP., vol. 18, no. 1, 3 January 2017 (2017-01-03), pages 41 - 53
   CARDENAS ME; BIANCHI A; DE LANGE T: "A Xenopus egg factor with DNA-binding properties characteristic of terminus-specific telomeric proteins", GENES DEV., vol. 7, no. 5, May 1993 (1993-05-01), pages 883 - 94, XP000610863
   DE LANGE T: "Activation of telomerase in a human tumor", PROC NATL ACAD SCI U S A., vol. 91, no. 8, 12 April 1994 (1994-04-12), pages 2882 - 5, XP001061780, DOI: doi:10.1073/pnas.91.8.2882

DOI:   http://dx.doi.org/10.1073/pnas.91.8.2882
   DE LANGE T; SHIUE L; MYERS RM; COX DR; NAYLOR SL; KILLERY AM; VARMUS LIE: "Structure and variability of human chromosome ends", MOL CELL BIOL., vol. 10, no. 2, February 1990 (1990-02-01), pages 518 - 27
   JIN, JIANJIAN: "Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes (TIL) in Gas-Permeable Flasks to Numbers Needed for Patient Treatment", J IMMUNOTHER, vol. 35, no. 3, April 2012 (2012-04-01), pages 283 - 292, XP002778973, DOI: doi:10.1097/CJI.0b013e31824e801f

DOI:   http://dx.doi.org/10.1097/CJI.0b013e31824e801f
   JAEGER HM; NAGEL SR: "Physics of the granular state", SCIENCE, vol. 255, no. 5051, 20 March 1992 (1992-03-20), pages 1523 - 31
   O. R. MUSIN: "The problem of the twenty-five spheres", RUSS. MATH. SURV., vol. 58, no. 4, 2003, pages 794 - 795
   DUDLEY, M. E. ET AL.: "Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma", J CLIN ONCOL, vol. 23, 2005, pages 2346 - 2357, XP002433186, DOI: doi:10.1200/JCO.2005.00.240

DOI:   http://dx.doi.org/10.1200/JCO.2005.00.240
   CHANDRAN, S. S. ET AL.: "Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study", LANCET ONCOL, 2017
   STEVANOVIC, S. ET AL.: "Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells", J CLIN ONCOL, vol. 33, 2015
   "FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing", CONTROL (CMC) INFORMATION FOR HUMAN GENE THERAPY INVESTIGATIONAL NEW DRUG APPLICATIONS (INDS, 2008
   RICHARDS JO; TREISMAN J; GARLIE N; HANSON JP; OAKS MK: "Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures", CYTOMETRY A, vol. 81, 2012, pages 374 - 81
   GOFF ET AL.: "Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma", J CLIN ONCOL., vol. 34, no. 20, 10 July 2016 (2016-07-10), pages 2389 - 97
   SARNAIK A; KLUGER H; CHESNEY J ET AL.: "Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy", J CFIN ONCOL., vol. 35, 2017
OppositionWO2018182817
 EP3601533
 US8383099
   JIN ET AL.: "Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment", J IMMUNOTHER, vol. 35, no. 3, April 2012 (2012-04-01), XP055568014, DOI: 10.1097/CJI.0b013e31824e801f

DOI:   http://dx.doi.org/10.1097/CJI.0b013e31824e801f
   IKARASHI ET AL.: "Solid-phase Anti- CD 3 Antibody Activation and Cryopreservation of Human Tumor-infiltrating Lymphocytes Derived from Epithelial Ovarian Cancer", JPN. J. CANCER RES., vol. 83, December 1992 (1992-12-01), pages 1359 - 1365, XP009186820, DOI: 10.1111/j.1349-7006.1992.tb02770.x

DOI:   http://dx.doi.org/10.1111/j.1349-7006.1992.tb02770.x
   WOLF WILSON: "Superior Cell Culture Devices, G-Rex", G-REX-BROCHURE, 31 October 2016 (2016-10-31), pages 1 - 2, XP055871481, Retrieved from the Internet [retrieved on 20211210]
   BAJGAIN ET AL.: "Optimizing the production of suspension cells using the G-Rex ''M'' series", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOPMENT, vol. 1, 2014, pages 14015, XP055517156, DOI: 10.1038/mtm.2014.15

DOI:   http://dx.doi.org/10.1038/mtm.2014.15
   ITZHAKI ORIT, ET AL: "Establishment and Large-scale Expansion of Minimally cultured Young Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy", J IMMUNOTHER ., vol. 34, no. 2, 1 March 2011 (2011-03-01), pages 212 - 220, XP055871483
   TRAN ET AL.: "Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy", J IMMUNOTHER, vol. 31, no. 8, pages 742 - 751, XP055031158, DOI: 10.1097/CJI.0b013e31818403d5

DOI:   http://dx.doi.org/10.1097/CJI.0b013e31818403d5
   DUDLEY MARK E., ET AL: "CD8+ Enriched Young Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 16, no. 24, 15 December 2010 (2010-12-15), US, pages 6122 - 6131, XP055871484, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-1297

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-10-1297
   BESSER ET AL.: "Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients", CLIN CANCER RES, vol. 16, no. 9, 1 May 2010 (2010-05-01), XP055448438, DOI: 10.1158/1078-0432.CCR-10-0041

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-10-0041
   LEE ET AL.: "Tumor-infiltrating lymphocytes in melanoma", CURR ONCOL REP., vol. 14, no. 5, October 2012 (2012-10-01), pages 468 - 474, XP035106577, DOI: 10.1007/s11912-012-0257-5

DOI:   http://dx.doi.org/10.1007/s11912-012-0257-5
   QUNRUI YE ET AL: "Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, vol. 9, no. 1, 9 August 2011 (2011-08-09), pages 1 - 13, XP021105653, ISSN: 1479-5876, DOI: 10.1186/1479-5876-9-131

DOI:   http://dx.doi.org/10.1186/1479-5876-9-131
   ROSENBERG ET AL.: "A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes", SCIENCE, vol. 19, no. 233, 1986, pages 1318 - 21, XP000196187, DOI: 10.1126/science.3489291

DOI:   http://dx.doi.org/10.1126/science.3489291
   ROSENBERG ET AL.: "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma", N ENGL J MED., vol. 319, 1988, pages 1676 - 80, XP009032797
   ROSENBERG ET AL.: "Treatment of Patients with Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2", J. NATL. CANCER INST., vol. 86, no. 15, 1994, pages 1159 - 66, XP009082760, DOI: 10.1093/jnci/86.15.1159

DOI:   http://dx.doi.org/10.1093/jnci/86.15.1159
   FORGET ET AL.: "The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity", ONCOLMMUNOLOGY, vol. 5, no. 2, February 2016 (2016-02-01), XP055441686, DOI: 10.1080/2162402X.2015.1057386

DOI:   http://dx.doi.org/10.1080/2162402X.2015.1057386
   VIKTORIA GONTCHAROVA: "Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma", POSTER FROM AACR ANNUAL MEETING, 1 April 2019 (2019-04-01), pages 14, XP093165404
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.